1 Ribociclib is manufactured by Novartis for early breastcancer and advanced or metastatic breastcancer. 2 The approval was supported by the NATALEE (NCT03701334) trial, a randomized, open ...
Novartis said its Kisqali breastcancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along with endocrine therapy (ET) reduced the ...
Results that may be inaccessible to you are currently showing.